Nazari Mahsa, Alikhani Mina, Nekooei Sirous, Abnous Khalil, Taghdisi Seyed Mohammad, Saljooghi Amir Sh, Ramezani Mohammad, Alibolandi Mona
Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Int J Pharm. 2025 May 15;676:125621. doi: 10.1016/j.ijpharm.2025.125621. Epub 2025 Apr 18.
Covalent organic frameworks (COFs) are a novel class of organic porous materials that, in recent years, have gained much attention for their applications as nanocarriers toward nanomedicine development. Inspired by this, we introduce for the first time a novel theranostic nanoplatform that combines iodine ligand 5-amino-2,4,6-triiodoisophthalic acid (ATIPA)-decorated porphyrin-based covalent organic frameworks (pCOF-I) designed for effective photodynamic therapy (PDT), doxorubicin (DOX) encapsulation, and computed tomography (CT) imaging toward melanoma treatment. In the design of this COF, we have successfully integrated the iodine ligand with porphyrin. The synthesized mesoporous nanoplatform was loaded with DOX and further modified by COOH-PEG-NH, which was conjugated with the AS1411 aptamer to be targeted to B16F0 melanoma cells. Comprehensive characterizations verified the successful synthesis and controlled release of DOX from the synthesized COF. In vitro evaluation against B16F0 showed combined chemo-PDT therapy. In addition, higher cellular uptake and toxicity were observed for the targeted platform compared to the non-targeted one towards B16F0. The porphyrin molecules imparted to the pCOF-I nanoparticles (NPs) a significant capacity for light-induced reactive oxygen species (ROS) generation, demonstrating remarkable PDT efficacy in both in vivo and in vitro environments. An in vivo investigation on B16F0 ectopic tumor model of melanoma in mice confirmed the potential for showed combined chemo-PDT therapy chemo-PDT in preclinical stage while approving guided delivery and tumor accumulation of AS1411 aptamer-tagged systems. On the other hand, the prepared platform demonstrated desirable CT-scan imaging of B16F0 tumorized mice 6 and 24 h post-injection. Notably, this is the first report of an AS1411 aptamer-targeted pCOF-I system for CT imaging-guided combined chemo-PDT, marking a significant step forward in multimodal cancer treatment strategies.
共价有机框架(COFs)是一类新型的有机多孔材料,近年来,因其作为纳米载体在纳米医学发展中的应用而备受关注。受此启发,我们首次引入了一种新型的诊疗纳米平台,该平台结合了碘配体5-氨基-2,4,6-三碘间苯二甲酸(ATIPA)修饰的卟啉基共价有机框架(pCOF-I),用于有效的光动力疗法(PDT)、阿霉素(DOX)封装以及针对黑色素瘤治疗的计算机断层扫描(CT)成像。在该COF的设计中,我们成功地将碘配体与卟啉整合在一起。合成的介孔纳米平台负载了DOX,并进一步用COOH-PEG-NH进行修饰,后者与AS1411适配体偶联,以靶向B16F0黑色素瘤细胞。全面的表征验证了合成的COF中DOX的成功合成和控释。针对B16F0的体外评估显示了联合化学-光动力疗法。此外,与非靶向平台相比,靶向平台对B16F0的细胞摄取和毒性更高。卟啉分子赋予pCOF-I纳米颗粒(NPs)显著的光诱导活性氧(ROS)生成能力,在体内和体外环境中均显示出显著的光动力疗法疗效。对小鼠黑色素瘤B16F0异位肿瘤模型的体内研究证实了在临床前阶段联合化学-光动力疗法的潜力,同时证实了AS1411适配体标记系统的靶向递送和肿瘤积累。另一方面,制备的平台在注射后6小时和24小时对B16F0荷瘤小鼠显示出理想的CT扫描成像。值得注意的是,这是关于AS1411适配体靶向的pCOF-I系统用于CT成像引导的联合化学-光动力疗法的首次报道,标志着多模态癌症治疗策略向前迈出了重要一步。